National Medical Products Administration (NMPA) formerly CFDA has conducted inspection of two sites for CanSino, Bio COVID Vaccine Phase III study in Pakistan in Feb 2021.  After a detailed evaluation of study data, interview with the site, CRO and sponsor personnel; they have given satisfactory remarks on the development, conduct and data quality of the study.

It is expected that CanSino, Bio will also get regulatory approval for their COVID-19 vaccine in China. Dimension Research personnel was part of this first ever, historical Chinese regulatory body inspection of a new molecule in Pakistan.

Dimension Research feel honored to be part of drug development team for this COVID 19 vaccine which will give protection to millions of Pakistanis, Chinese and people all over the world.